2022 Alert # 8:
Test for Legionella in Adults with Pneumonia

- Most Legionnaires’ disease cases occur from June to October in New York City.
- The NYC Health Department is currently responding to a cluster of Legionnaires’ disease cases in the Highbridge area of the Bronx.
- Follow guidelines, and test for Legionella in adults with pneumonia, particularly patients who are ≥ 50 years or have lung disease, immune-suppression, or a history of smoking.
- Testing for Legionella includes both urine antigen testing and culture of sputum or bronchoalveolar lavage specimens.
- Report cases promptly to the NYC Health Department and submit all Legionella isolates to the Public Health Laboratory for sub-typing.

Please distribute to all clinical staff in Internal Medicine, Geriatrics, Primary Care, Infectious Diseases, Emergency Medicine, Family Medicine, Laboratory Medicine, and Infection Control.

May 25, 2022

Dear Colleagues,

Legionnaires’ disease follows a seasonal pattern in New York City (NYC), with an increased number of cases reported from June to October each year. The Health Department is actively responding to a cluster of Legionnaires’ disease cases in the Highbridge area of the Bronx, which as of May 25, 2022 includes 19 cases and 1 death. Providers should test for Legionella when evaluating adults with symptoms of pneumonia. Testing should include both urine antigen testing (UAT) and Legionella sputum/respiratory culture. Identification and diagnostic testing of Legionnaires’ disease is critical for information treatment decisions and helping the Health Department identify and address outbreaks, particularly through matching of clinical isolates to environmental isolates.

Legionnaires’ disease is caused by Legionella bacteria. It is characterized by pneumonia occurring 2-14 days after exposure to an often-unidentified environmental source. Legionella is a ubiquitous aquatic organism that grows in warm environments (77°–108°F). Exposure occurs through inhalation of contaminated aerosols from devices such as cooling towers, whirlpool spas, showers, and faucets, and through aspiration of contaminated water. Groups at higher risk include persons > 50 years old, cigarette smokers, and persons with chronic lung disease, or persons with immunocompromising conditions. The case-fatality rate is estimated to be 10% for community-acquired Legionnaires’ disease. Recommended treatment options include macrolide or quinolone antibiotics.

Diagnostic Testing
Culture of the organism from respiratory secretions or tissues is the gold standard for diagnosis and should be used in conjunction with the Legionella UAT (which is specific for Legionella pneumophila, serogroup 1). Culture has the added benefits of identifying non-pneumophila Legionella, and non-serogroup 1 Legionella pneumophila, that may cause infection and of generating isolates that can be further analyzed using molecular techniques. Molecular comparison of clinical and environmental isolates grown in culture allows the Health Department to identify linked
clusters of infection as well as potential environmental sources of these infections. UAT alone does not allow for these critical public health investigations and may not detect other *Legionella* species and serogroups, besides *L. pneumophila*, serogroup 1.

Please note the following regarding the diagnosis of legionellosis:

- Simultaneously **test and treat** for legionellosis. Early treatment results in better outcomes.
- Order urine antigen testing (UAT) and culture on sputum or other appropriate respiratory specimens to test for *Legionella*.
  - *Legionella* culture requires the use of specialized media. Please alert your microbiology laboratory that legionellosis is in your differential diagnosis so that the correct testing is performed. The best specimens for culturing *Legionella* are sputum or bronchoalveolar lavage fluid. Collect specimens prior to the start of antibiotic therapy.
  - Urine antigen testing (UAT) is widely available as a rapid method for diagnosing Legionnaires’ disease. UAT is most sensitive for detecting *L. pneumophila* serogroup 1. Although *L. pneumophila* serogroup 1 accounts for most laboratory confirmed *Legionella* cases, a negative UAT does not rule out infection with other species and serotypes. Providers should also obtain specimens for culture to diagnose legionellosis.
- Serologic diagnosis is less useful for diagnosing acute infection and requires paired sera, collected 3–4 weeks apart, to detect a fourfold rise in antibody titer to a level > 1:128. A single antibody titer is not diagnostic for legionellosis; convalescent serum must be obtained for comparison.

Additional information for clinicians on Legionnaires’ disease is available at the Centers for Disease and Control and Prevention’s Legionnaires Disease Resource Site: [cdc.gov/legionella/clinicians](http://cdc.gov/legionella/clinicians)

**Recommendations for Providers**

To help the NYC Health Department identify outbreaks of Legionnaires’ disease:

- Maintain a high index of suspicion for legionellosis among all adults with pneumonia, whether community-acquired or nosocomial, especially during the summer and early fall.
- Keep in mind that symptoms of COVID-19 and Legionnaires’ disease are similar and testing is required to differentiate between these respiratory diseases.
- Specifically request both culture and UAT for *Legionella* diagnosis, and collect appropriate specimens for testing.
- Report all Legionnaires’ disease cases to the NYC Health Department by calling the Provider Access Line at [1-866-692-3641](tel:+18666923641).
- Send all *Legionella* isolates to the NYC Public Health Laboratory for serotyping and molecular testing. Laboratories should send isolates using PHL eOrder (available at [https://a816-phleorder.nyc.gov/PHLeOrder/](https://a816-phleorder.nyc.gov/PHLeOrder/)). Select the “Legionella serotyping” option and send isolates with a requisition form to:

  Public Health Laboratory  
  455 First Ave, Room 136  
  New York, NY 10016

For laboratory-related questions, please call the PHL Microbiology Section at [212-447-6783](tel:+12124476783).

As always, we appreciate our ongoing collaboration with NYC healthcare providers to help us address Legionnaires’ disease, as well as other infectious disease concerns in the city.
Celia Quinn, MD, MPH
Deputy Commissioner, Division of Disease Control